Comparing Kesimpta vs Vumerity
Kesimpta (ofatumumab) | Vumerity (diroximel fumarate) |
|
---|
Kesimpta (ofatumumab) | Vumerity (diroximel fumarate) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Multiple Sclerosis. Kesimpta may also be used for purposes not listed in this medication guide. |
Prescription only
Vumerity (generic name: diroximel fumarate) is an oral prescription medicine indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults. It is given as a twice-daily medicine... View more |
||||||||||||||||
More about Kesimpta (ofatumumab) | More about Vumerity (diroximel fumarate) | ||||||||||||||||
Ratings & Reviews | |||||||||||||||||
Kesimpta has an average rating of 6.8 out of 10 from a total of 74 ratings on Drugs.com. 51% of reviewers reported a positive effect, while 19% reported a negative effect. |
Vumerity has an average rating of 8.7 out of 10 from a total of 7 ratings on Drugs.com. 86% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Kesimpta side effects |
View all Vumerity side effects |
||||||||||||||||
Drug Class | |||||||||||||||||
Generic Availability | |||||||||||||||||
N/A |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Kesimpta prices |
View all Vumerity prices |
||||||||||||||||
Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
Brand Names | |||||||||||||||||
Other ofatumumab brands include: Arzerra |
N/A |
||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
1476 hours |
1 hour |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | |||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | |||||||||||||||||
A total of 175 drugs are known to interact with Kesimpta:
|
A total of 636 drugs are known to interact with Vumerity:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
Disease Interactions | |||||||||||||||||
First Approval Date | |||||||||||||||||
N/A |
October 29, 2019 |
||||||||||||||||
WADA Class View classifications | |||||||||||||||||
N/A |
N/A |
||||||||||||||||
More Information | |||||||||||||||||
Patient Resources | |||||||||||||||||
Professional Resources | |||||||||||||||||
Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.